For your patients

Alvesco^® is indicated for the treatment of persistent asthma and may help to optimize asthma treatment:

• Once-daily dosing
  Convenient once-daily dosing coupled with Alvesco^®’s unique pharmacological properties may improve patient compliance¹ and removes the need for mouth-rinsing following administration.
  
  
• Improved lung function
  Alvesco^® improves lung function in patients with mild-to-moderate as well as severe asthma.^2,3 It also improves measures of small airway function.^4-6
  
  
• Well-tolerated
  Alvesco^® possesses an excellent local and systemic tolerability profile.^7-9 The incidence of oropharyngeal side effects is low^7,8 and cortisol levels are not suppressed even at high concentrations,⁹ which may help to ease your patients’ fears of steroid-associated side effects.

Alvesco^® controls underlying asthma inflammation in the large and small airways.^2-6 To find out which patients may benefit most from Alvesco^®’s excellent distribution to the small airways,¹⁰ see the Patient profiles section.

In this section you can also find helpful resources for your patients who have been diagnosed with asthma. These include videos on how to use Alvesco^® correctly, with or without a spacer and guidance on choosing the right inhaler.

References:

1. Guest JF, davie AM, Ruiz FJ, et al. Switching  asthma patient to a once-daly inhaled steroid improves compliance and reduces healthcare costs. Prim Car Restpir J 2005;14(2):88-98
2. Dahl R, Engelstätter R, Trebas-Pietraś E, et al. A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma. Respir Med 2010;104:1121-1130.
3. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of inhaled ciclesonide compared with chlorofluorocarbon beclomethasone dipropionate in adults with moderate to severe persistent asthma. Respirology 2007;12:573-80.
4. Cohen J, Douma WR, ten Hacken NH, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008;31:1213-1220.
5. Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int 2010;59:59-66.
6. Cohen J, Postma DS, Douma WR, et al. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011;37:532-540.
7. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005;45:146-152.
8. Bateman ED, Linhof AE, Homik L, et al. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21:264-275.
9. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5’ monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328-336.
10. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respi Med 2006: 100;375-384